Background. In order to analyze the prognostic role of node involvement in
advanced ovarian cancer, we have analyzed data from a randomized clinical t
rial on advanced ovarian cancer.
Methods. Cases were 456 women who entered a randomized multicentric clinica
l trial comparing two cisplatin-based schemes of treatment after cytoreduct
ive surgery for advanced stage III-IV ovarian cancer. They underwent select
ive pelvic and/or paraortic lymphadenectomy.
Results. A total of 161 (35.3%) cases had positive nodes. The frequency of
positive nodes was statistically significantly higher in FIGO stage IV than
in stage III. Also grade 3 tumors were more likely to have positive nodes
than grade 1-2 tumors. No association was observed between nodal status and
response to chemotherapy. The 3-year survival was 46.2 (standard error (SE
) = 3.4 based on 147 deaths) and 44.6 (SE = 4.4, based on 84 deaths), respe
ctively, in negative and positive node groups, The corresponding values, wh
en the analysis was performed considering only subjects with residual tumor
<1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE = 5.
7) and 62.4 (SE = 9.6).
Conclusions. We did not find any association between nodal status and survi
val. Particularly, nodal status was not a prognostic factor for survival in
the subgroup of women with residual tumor <1 cm or absent after cytoreduct
ive surgery. (C) 1999 academic Press.